尤瑞克林治疗急性进展性缺血性脑卒中临床疗效观察

Urinary kallidinogenase in treatment of acute progressive ischemic stroke in 100 cases

目的探讨尤瑞克林治疗急性进展性缺血性脑卒中的临床疗效和安全性。方法本院神经内科收治的200例72h发病的急性进展性缺血性脑卒中患者随机分成治疗组和常规组,各100例,两组给予相同的基础治疗(降压、降糖、调血脂、抗血小板聚集或抗凝药物、改善脑循环、营养脑细胞药物),但治疗组加用尤瑞克林0.15PNA单位静脉滴注,每日1次,连用1～2周,于治疗前后评定患者神经功能缺损程度、日常生活活动能力及不良反应事件。结果治疗后两组患者的神经功能缺损、日常生活活动能力均有所改善,与治疗前相比差异具有统计学意义(P<0.05);治疗组改善程度更明显,与常规组相比差异有显著统计学意义(P<0.01);治疗组较常规组不良反应无明显增加。结论尤瑞克林治疗能降低急性进展性缺血性脑卒中发病率,有利于急性进展性缺血性脑卒中患者神经功能恢复、提高日常生活活动能力,安全性可以肯定。

Objective To explore the efficacy and safety role of Urinary Kallidinogenase in treatment of acute progressive ischemic stroke. Methods 200 patients with acute progressive cerebral infarction within 72 hours of the onset were randomly divided into Urinary Kallidinogenase group and routine treatment group, 100 patients in each. The basically treatment of two groups are the same, including control blood pressure/ glucose/ LDL-C, anticoagulant drugs and given nutrition of brain ceils. Urinary Kallidinogenase group was administered intravenous drip once daily for 7 days or 14 days with 0.15PNA Urinary Kallidinogenase on the basis of routine treatment. The neurologic function deficits and ability of daily life of patients with acute progressive ischemic stroke and safety were evaluated before and after the treatment. Results The difference of neurologic function deficits and ability of daily life after treatment in two groups were improved, which compared with before treatment was statistically significant （ P 〈 0.05 ）. Urinary Kallidinogenase group improved more remarkably, compared with the routine treatment group was statistically different significance （P 〈 0. 01 ）. The treatment group than in the routine treatment group no remarkable increase in adverse reaction. Conclusions Urinary Kallidinogenase group can decrease the incidence of acute progressive ischemic stroke and improve neurologic function deficit and ability of daily life and safety in acute progressive ischemic stroke.